This is a news story, published by Yahoo, that relates primarily to Lykos Therapeutics news.
For more Lykos Therapeutics news, you can click here:
more Lykos Therapeutics newsFor more mental health treatments news, you can click here:
more mental health treatments newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
psychedelic drug MDMA. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest several psychedelic drugs news, ecstasy news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
benefit corporation Lykos TherapeuticsReuters
•79% Informative
A panel of advisers to the U.S. Food and Drug Administration will meet on Tuesday to discuss a therapy based on the psychedelic drug MDMA for patients with PTSD.
The meeting by the agency's independent experts is the farthest a drug based on MDMA has ever reached in the FDA regulatory process for approval.
The treatment is a capsule form of MDMA made by the public-benefit corporation Lykos Therapeutics .
VR Score
88
Informative language
94
Neutral language
64
Article tone
semi-formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links